Pre-term birth drug

Here's one to watch:

U.S. Food and Drug Administration staff questioned the effectiveness of Adeza Biomedical Corp.'s Gestiva drug because new findings were at odds with an earlier government-funded trial, according to documents released on Monday.

Data for the drug, which aims to prevent pre-term births, also showed a possible increase in miscarriages and stillbirths in women who used it, the agency staff said ahead of an FDA advisory panel scheduled to discuss the drug on Tuesday.

(link)